Exec Chat: New CEO Of Digital Therapeutics Alliance Says Reimbursement Remains Big Issue
Executive Summary
In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.
You may also be interested in...
Pear Bankruptcy Filing Highlights Difficult Challenges Facing Digital Therapeutics
Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.
Big Health Digital Therapeutics Rings In 2022 With $75M Financing, FDA Alum On Board
Big Health will use its $75m in new funding to scale the business, with plans to launch six new digital therapeutics by 2024. Former US FDA official Anand Shah will join its board of directors.
Pear CEO Sees Fulfilment And Reimbursement Challenges Ahead
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.